REV-ERB agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
ligation The joining of consecutive nucleotides in the same strand of a nucleic acid molecule via the formation of a phosphodiester bond between the 5'-phosphoryl terminus of one nucleotide and the 3'-hydroxyl terminus of an adjacent nucleotide, a condensation reaction catalyzed by enzymes known as ligases. This reaction occurs in fundamentally the same way in all varieties of DNA and RNA anabolism, natural or artificial, whether the addition of individual nucleotides to a growing strand (as in DNA replication and transcription), or the repair of nicks and cuts in previously intact molecules, or the joining of separate nucleic acid fragments into a single molecule (as in chromosomal crossover, exon splicing, retroviral transposition, and all other forms of genetic recombination, as well as artificial molecular cloning techniques). Ligation is the opposite of the catabolic reaction wherein phosphodiester bonds are cleaved by nucleases. It also should not be confused with the non-covalent base pairing that can occur between complementary strands; ligation refers specifically to the synthesis of the phosphate backbone of a single strand.
=== Other uses in further disambiguation === Academy of Applied Arts (disambiguation) Access All Areas (disambiguation) Addis Ababa Agreement (disambiguation) Again and Again (disambiguation) Ah Ah Ah (disambiguation) All About Adam (disambiguation) All American Airways (disambiguation) Ansel Adams Award (disambiguation) Army Appropriations Act (disambiguation) Axis and Allies (disambiguation) Ay Ay Ay (disambiguation)
On 6 October 2015, Microsoft unveiled the latest version of their Microsoft Surface Book laptop with a display of "over 6 million pixels" and their new phones the Microsoft Lumia 950 and 950 XL, which, aside from 4K video recording that their predecessors included, feature a display of "over 5 million pixels". On 8 December 2015, the ceremony of the opening of the Holy Door in Vatican City, which marked the beginning of the Jubilee Year of Mercy in the Roman Catholic church, was the first worldwide Ultra HD broadcast via satellite. The event was produced by the Vatican Television Center with the support of Eutelsat, Sony, Globecast and DBW Communication. The team did some advanced experimentation with 4K/High Dynamic Range live images and in particular using technology developed by the BBC's R&D division and Japan's public broadcaster NHK in terms of Hybrid Log Gamma (HLG) signals.
Sources: en.wikipedia.org
Episode Two features no new weapons. Instead, Valve explored further uses for the gravity gun, with which the player can pick up and throw large objects. They introduced more varied gravity gun "ammunition", such as logs, flares, and half-height butane tanks, which are easier to aim than full-size fuel drums. Near the end of the game, the player uses "Magnusson Devices", which designer Dario Casali described as a "sticky bomb that you fire at a Strider's underbelly that will draw power from the Strider's internal power source". The player uses the gravity gun to attach the bombs to tripodal enemy Striders; the bombs detonate when fired upon with any other of the player's weapons, instantly destroying the target. The Hunter escorts prioritize them as targets, either destroying them in the player's grasp or shooting already-attached ones off.
Also in 1934, scientists Ernest Rutherford, Mark Oliphant, and Paul Harteck, produced the radioisotope tritium (hydrogen-3, 3H) by hitting deuterium with high-energy nuclei. The deuterium used in the experiment was a generous gift of heavy water from UC Berkeley physicist Gilbert N. Lewis. Bombarding deuterium produced two previously undetected isotopes, helium-3 (3He) and 3H. Rutherford and his colleagues successfully created 3H, but incorrectly assumed that 3He was the radioactive component. The work of Luis Walter Alvarez and Robert Cornog first isolated 3H and reversed Rutherford's incorrect notion. Alvarez reasoned that tritium was radioactive, but did not measure the half-life, though calculations at the time suggested >10 years. At the end of World War II, physical chemist Willard Libby detected the residual radioactivity of a tritium sample with a Geiger counter, providing a more accurate understanding of the half-life, now accepted as 12.3 years.
== External links == GeneReviews/NCBI/NIH/UW entry on Maple Syrup Urine Disease Branched+Chain+Ketoacid+Dehydrogenase at the U.S. National Library of Medicine Medical Subject Headings (MeSH) EC 1.2.4.4 [1]
5p partial monosomy syndrome Bloom syndrome Branchiootorenal syndrome 1 Cardiofaciocutaneous syndrome 4 Christianson syndrome Congenital disorder of glycosylation, type IIw Congenital myasthenic syndrome 2A Congenital myopathy 4A, autosomal dominant Congenital myopathy 4B, autosomal recessive Creatine transporter deficiency Cutis laxa, X-linked Ehlers-Danlos syndrome, Beasley-Cohen type Granulocytopenia with immunoglobulin abnormality Hereditary spastic paraplegia 23 and 51 Intellectual disability, autosomal recessive 5 Intellectual disability, X-linked 107, 58, and 61 Knobloch syndrome Marfan syndrome Mitochondrial DNA depletion syndrome 13 Nance-Horan syndrome Oculofaciocardiodental syndrome Otofaciocervical syndrome 1 Proximal myopathy with extrapyramidal signs Radioulnar synostosis-developmental delay-hypotonia syndrome Renpenning syndrome Seckel syndrome 9 Severe X-linked myotubular myopathy SIN3A-related intellectual disability syndrome due to a point mutation Symphalangism-brachydactyly syndrome Syndromic X-linked intellectual disability 14 Torsion dystonia 4 X-linked intellectual disability with marfanoid habitus XFE progeroid syndrome
Sources: en.wikipedia.org
Some compounds such as 2C-B and 5-Meo-DiPT did eventually increase in popularity to the point that they were sold in pill form to reach a wider market, and acquired popular street names ("Nexus" and "Foxy," respectively). Once a chemical reaches this kind of popularity, it is usually just a matter of time before it is added to the list of scheduled (i.e., illegal) drugs. The late 1990s and early 2000s also saw the first widespread use of novel anabolic steroids by athletes in competition. Steroids had been banned by the International Olympic Committee since 1976, but due to the large number of different anabolic agents available for human and veterinary use, the ability of laboratories to test for all available drugs had always lagged behind the ability of athletes to find new compounds to use. The introduction of increasingly formalised testing procedures, especially with the creation of the World Anti-Doping Agency in 1999, made it much more difficult for athletes to get away with using these drugs without detection, which then led to the synthesis of novel and potent anabolic steroid drugs such as tetrahydrogestrinone (THG), which were not detectable by the standard tests.
AMP + diphosphate + NAD+ The 3 substrates of this enzyme are ATP, deamido-NAD+, and NH3, whereas its 3 products are AMP, diphosphate, and NAD+. This enzyme belongs to the family of ligases, specifically those forming carbon-nitrogen bonds as acid-D-ammonia (or amine) ligases (amide synthetase). The systematic name of this enzyme class is deamido-NAD+:ammonia ligase (AMP-forming). Other names in common use include NAD+ synthetase, NAD+ synthetase, nicotinamide adenine dinucleotide synthetase, and diphosphopyridine nucleotide synthetase. This enzyme participates in nicotinate and nicotinamide metabolism and nitrogen metabolism.
== History == Before the development of proximity labeling, determination of protein proximity in cells relied on studying protein-protein interactions through methods such as affinity purification-mass spectrometry and proximity ligation assays. DamID is a method developed in 2000 by Steven Henikoff for identifying parts of the genome proximal to a chromatin protein of interest. DamID relies on a DNA methyltransferase fusion to the chromatin protein to nonnaturally methylate DNA, which can then be subsequently sequenced to reveal genome methylation sites near the protein. Researchers were guided by the fusion protein strategy of DamID to create a method for site-specific labeling of protein targets, culminating in the creation of the biotin protein labelling-based BioID in 2012. Alice Ting and the Ting lab at Stanford University have engineered several proteins that demonstrate improvements in biotin-based proximity labeling efficacy and speed.
=== Peripheral tissues === Neuronostatin/GPR107 signaling is associated with regulation of COL4 within both breast cancer and kidney tissues, where Neuronostatin/GPR107 reduces expression of COL4. In breast cancer, this reduction in COL4 generates enlarged pores within the extracellular matrix that allow for increase breast cancer migration and proliferation, leading to increased rates of metastasis. Neuronostatin and GPR107 have similarly been linked to increased rates of migration within prostate cancer. Within kidney tissues, Neuronostatin/GPR107 reduces thickening/remodeling of the glomerular basement membrane by reducing COL4 deposition and improves features of diabetic nephropathy Additional features of Neuronostatin signaling include regulation of cardiomyocytes; Neuronostatin depresses cardiomyocyte function by affecting [Ca2+]i responses and regulating the expression of calcium regulating proteins
=== May === May 1 Iran war: President Donald Trump notifies lawmakers in Congress that the Iran war has been "terminated" ahead of a 60-day deadline under the War Powers Resolution which military operations must halt unless lawmakers authorize military force. 2026 May Day protests: May Day protests are held across the U.S., including an economic blackout as part of 3,500 "May Day Strong" events across the country. Additionally, demonstrations are held outside institutions such as the New York Stock Exchange. British singer Zayn Malik cancels all U.S. concert events for his upcoming Konnakol tour after being hospitalized for an unknown illness. May 2 2026 Kentucky Derby: In horse racing, American racehorse Golden Tempo wins the 152nd Kentucky Derby after entering the race with a 24–1 odds, making Cherie DeVaux the first female trainer to win the derby. Spirit Airlines announces it has gone out of business after 34 years. May 3 – Iran war: President Trump announces Operation Project Freedom in an effort to secure commercial traffic across the Strait of Hormuz. May 4 Iran war: The U.S. Central Command confirms the launch of Operation Project Freedom in an effort to secure commercial traffic across the Strait of Hormuz. Danish shipping company Maersk reports that the Alliance Fairfax, a US-flagged vehicle carrier operated by subsidiary Farrell Lines, has successfully crossed the Strait of Hormuz accompanied by U.S. military assets as part of Project Freedom. Iran is reported to have fired missiles and drones at military and commercial ships.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.